Tag: Novartis

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market cap and sales.

Novartis creates Biome innovation initiative to develop digital health technology

Novartis AG launched Novartis Biome, a digital innovation lab and series of open innovation initiatives, to help the pharma identify and develop digital health technology.

Boston Pharmaceuticals licenses three anti-infective programs from Novartis

antimicrobial resistance
Novartis has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates.

Cellular Biomedicine Group strikes a CAR-T deal with Novartis

Cellular Biomedicine Group (China) announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah in China.

GARDP and Novartis to cooperate on enhancing generic antibiotics

microbiology plates
The Global Antibiotic Research & Development Partnership (GARDP) and Novartis are joining forces to accelerate the development and availability of generic antibiotic treatments for children.

Eyecare unit of Novartis will move its HQ to Switzerland

Alcon, the eyecare unit of Novartis that will be spun off as a separate company in 2019, plans to move its corporate headquarters from Texas to Geneva, according to a statement by Novartis.

Novartis sells parts of its Sandoz US portfolio to Aurobindo Pharma

Novartis announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma.

Novartis to invest $91.5 million in cell and gene therapies manufacturing

The pharma giant Novartis has announced plans to invest $91.5 million over three years on a production site for cell and gene therapies. The goal is to enable new treatments to be delivered in Europe.

Chinese biotech signed two-drug deal with Novartis

Laekna announced the signing of an agreement with Novartis for exclusive global rights to develop and commercialize two oral Novartis clinical-stage oncology assets.

Albumedix announced collaboration with Novartis

Novartis and Albumedix have entered into an agreement to evaluate the development of several first-in-class therapeutics using Albumedix’s Veltis® technology platform and associated technologies.

European Commission approved Novartis migraine drug

Novartis announced that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month.

Investments in cytostatics production will exceed 3 billion rubles

The Ryazan region has been interacting with the company "Pharmimex", which is developing the Skopinpharm production complex in the Skopinsky district.

Novartis buys exclusive rights to a promising dermatologic drug

Novartis announced that it has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) regarding their compound MOR106.

French CDMO will manufacture innovative cancer treatments for Novartis

Novartis signed an agreement with CELLforCURE to produce innovative cancer treatments known as CAR-T therapies (chimeric antigen receptor T-cells) at the bioproduction site based in Les Ulis (Essonne).

Regenxbio receives $100 million license payment from Novartis

REGENXBIO announced that it has received an accelerated license payment of $100 million under its license agreement with AveXis, due to the acquisition of AveXis by Novartis.

Top pharma players place their stakes on Chinese market

china street
Pharmaceutical giant Bayer reported a robust growth in its pharmaceutical business in China, as its total sales stood at 17 billion yuan ($2.67 billion) in 2017, a year-on-year growth of 18.3 percent.

Novartis launched its novel FocalView clinical trials application

Novartis announced the launch of FocalView, an ophthalmic digital research platform. FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients.